Arvinas (ARVN) Metrics: History & Chart

Arvinas, Inc.(ARVN)

Biotechnology · New Haven, CT

$7.31-0.15 (-2.01%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Arvinas, Inc.

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.

New Haven, CT

246 employees

www.arvinas.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Randy Teel

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-0.67%
30D Total Return	-20.55%
YTD Total Return	-37.10%
1Y Total Return	-22.37%
3Y Total Return	-59.93%
5Y Total Return	-90.95%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-37.10%
2025	-38.13%
2024	-53.43%
2023	+20.32%
2022	-58.35%
2021	-3.29%
2020

CAGR TTM	-22.28%
CAGR 3Y	-26.27%
CAGR 5Y	-38.16%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	46.62
PE Ratio Avg TTM	54.09
PE Ratio Avg 3Y	54.09
Current VS TTM Avg	-13.81%
Current VS 3Y Avg	-13.81%
Current VS 5Y Avg	-13.81%

All Metrics

ARVN Valuation Metrics

ARVN Stock Price Metrics

ARVN Dividend Metrics

ARVN Growth Rate Metrics

ARVN Discounted Cash Flow Metrics

ARVN Returns By Period

ARVN Yearly Returns

ARVN Average Annual Returns By Period (CAGR)

ARVN Revenue Metrics

ARVN PE Ratio Metrics

ARVN PS Ratio Metrics

ARVN PB Ratio Metrics

ARVN Price to Free Cash Flow Ratio Metrics

ARVN Debt to Equity Ratio Metrics

ARVN PEG Ratio Metrics

ARVN FCF Yield

ARVN Earnings Yield

ARVN EBITDA Yield

ARVN OCF Yield

ARVN EV/EBIT Ratio Metrics

ARVN EV/EBITDA Ratio Metrics

ARVN EV/Assets Ratio Metrics

ARVN EV/Sales Ratio Metrics

ARVN Current Ratio Metrics

ARVN Quick Ratio Metrics

ARVN ROIC Metrics

ARVN Return on Assets Metrics

ARVN Return on Equity Metrics

ARVN Net Profit Margin Metrics

ARVN Gross Profit Margin Metrics

ARVN Tax Rate Metrics

PS Ratio	1.55
PS Ratio Avg TTM	2.57
PS Ratio Avg 3Y	9.33
Current VS TTM Avg	-39.59%
Current VS 3Y Avg	-83.38%
Current VS 5Y Avg	-87.68%

PB Ratio	0.87
PB Ratio Avg TTM	1.42
PB Ratio Avg 3Y	2.17
Current VS TTM Avg	-38.60%
Current VS 3Y Avg	-59.82%
Current VS 5Y Avg	-67.42%

PFCF Ratio	4.31
PFCF Ratio Avg TTM	5.51
PFCF Ratio Avg 3Y	5.54
Current VS TTM Avg	-21.80%
Current VS 3Y Avg	-22.26%
Current VS 5Y Avg	-62.31%

Debt/Equity Ratio	0.01
Debt/Equity Ratio Avg TTM	0.02
Debt/Equity Ratio Avg 3Y	0.01
Current VS TTM Avg	-18.88%
Current VS 3Y Avg	+21.00%
Current VS 5Y Avg	+34.91%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	23.21%
FCF Yield Avg TTM	18.77%
FCF Yield Avg 3Y	18.69%
Current VS TTM Avg	+23.66%
Current VS 3Y Avg	+24.18%
Current VS 5Y Avg	+65.34%

Earnings Yield	2.14%
Earnings Yield Avg TTM	1.86%
Earnings Yield Avg 3Y	1.86%
Current VS TTM Avg	+15.05%
Current VS 3Y Avg	+15.05%
Current VS 5Y Avg	+15.05%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.60
Ev/Assets Ratio Avg TTM	0.80
Ev/Assets Ratio Avg 3Y	1.02
Current VS TTM Avg	-24.81%
Current VS 3Y Avg	-41.23%
Current VS 5Y Avg	-51.39%

Ev/Sales Ratio	1.28
Ev/Sales Ratio Avg TTM	2.26
Ev/Sales Ratio Avg 3Y	8.81
Current VS TTM Avg	-43.36%
Current VS 3Y Avg	-85.48%
Current VS 5Y Avg	-89.10%

Current Ratio	7.91
Current Ratio Avg TTM	5.92
Current Ratio Avg 3Y	4.61
Current VS TTM Avg	+33.52%
Current VS 3Y Avg	+71.46%
Current VS 5Y Avg	+58.67%

Quick Ratio	7.91
Quick Ratio Avg TTM	5.92
Quick Ratio Avg 3Y	4.61
Current VS TTM Avg	+33.52%
Current VS 3Y Avg	+71.46%
Current VS 5Y Avg	+58.67%

ROIC	(2.19%)
ROIC Avg 3Y	(29.29%)
ROIC Avg 5Y	(26.42%)
Current VS 3Y Avg	+92.52%
Current VS 5Y Avg	+91.71%
Current VS 10Y Avg	+92.19%

ROA	1.38%
ROA Avg TTM	(0.82%)
ROA Avg 3Y	(5.82%)
Current VS TTM Avg	+269.14%
Current VS 3Y Avg	+123.72%
Current VS 5Y Avg	+124.85%

ROE	1.65%
ROE Avg TTM	(19.29%)
ROE Avg 3Y	(37.55%)
Current VS TTM Avg	+108.55%
Current VS 3Y Avg	+104.39%
Current VS 5Y Avg	+104.46%

Net Profit Margin	2.94%
Net Profit Margin Avg TTM	(273.57%)
Net Profit Margin Avg 3Y	(124.20%)
Current VS TTM Avg	+101.07%
Current VS 3Y Avg	+102.37%
Current VS 5Y Avg	+101.66%

Gross Profit Margin	96.43%
Gross Pft Margin Avg TTM	95.34%
Gross Pft Margin Avg 3Y	98.04%
Current VS TTM Avg	+1.14%
Current VS 3Y Avg	-1.64%
Current VS 5Y Avg	-0.11%

Tax Rate	0.12%
Tax Rate Avg 3Y	0.18%
Tax Rate Avg 5Y	0.18%
Current VS 3Y Avg	-34.23%
Current VS 5Y Avg	-34.23%
Current VS 10Y Avg	-34.23%